Streetbeat News

Stock Prices

AEMD

ALLR

APLM

BDSX

CALT

CRBU

CRIS

INBS

ISPC

IXHL

NAUT

NYMX

During Thursday's pre-market session, several healthcare stocks saw significant movement. Incannex Healthcare, Caribou Biosciences, Biodesix, iSpecimen, Aethlon Medical, and Intelligent Bio Solutions all saw increases, with Incannex leading the pack with a 32.2% rise. On the other hand, Allarity Therapeutics, Nymox Pharmaceutical, Nautilus Biotechnology, Calliditas Therapeutics, Curis, and Apollomics all experienced decreases, with Allarity seeing the largest drop of 52.3%.

Portfolio Pulse from Benzinga Insights

July 06, 2023 | 1:12 pm

CEAD

DSS

FRGT

ISUN

NCRA

OPXS

PIXY

PPSI

RCRT

SPIR

VIEW

VINO

During Thursday's pre-market session, 12 industrial stocks showed significant movement. Gainers included Recruiter.Com Group, iSun, View, DSS, Pioneer Power Solutions, and Spire Global. Losers included Nocera, Freight Technologies, CEA Industries, ShiftPixy, Gaucho Group Holdings, and Optex Systems Hldgs.

Portfolio Pulse from Benzinga Insights

July 06, 2023 | 1:12 pm

IFBD

OST

In Thursday's pre-market session, several information technology stocks saw significant movement. Infobird Co, Borqs Technologies, Blend Labs, Ebix, Stronghold Digital Mining, and Powerbridge Technologies all saw increases, with Infobird Co leading the gainers with a 12.9% increase. On the other hand, Ostin Technology Group, IDEX Biometrics, Casa Systems, CLPS, ZeroFox Holdings, and WM Tech all experienced declines, with Ostin Technology Group leading the losers with a 13.1% decrease.

Portfolio Pulse from Benzinga Insights

July 06, 2023 | 1:12 pm

USO

OPEC's forecast for oil demand growth in 2024 is expected to be lower than the growth it expects this year of 2.35 million barrels per day, or 2.4%.

Portfolio Pulse from Benzinga Newsdesk

July 06, 2023 | 1:12 pm

ASLN

ASLAN Pharmaceuticals Ltd (NASDAQ:ASLN) released topline data from its TREK-AD Phase 2b study of eblasakimab in adult patients with moderate-to-severe atopic dermatitis. The drug met the primary endpoint in three dosing arms with statistical significance. However, the 400mg Q4W dosing arm did not meet the primary or secondary endpoints. Further data is expected in Q4 2023 and a Phase 3 clinical development program is planned for 2024. ASLN shares were down by almost 14% in the premarket but have since recovered.

Portfolio Pulse from Vandana Singh

July 06, 2023 | 1:09 pm

LZM

Lifezone Metals has completed its business combination with GoGreen Investments, creating the first pure-play nickel resource and cleaner technology company listed on the NYSE. The company's shares and warrants are expected to start trading under the ticker symbols 'LZM' and 'LZMW'. The transaction brought in gross proceeds of approximately $86.6 million for Lifezone Metals. The company has received strong support from the U.S. and Tanzanian governments, highlighting Tanzania's importance as a key emerging supplier of critical minerals.

Portfolio Pulse from Happy Mohamed

July 06, 2023 | 1:07 pm

CRIS

Curis, Inc. (NASDAQ:CRIS) shares dropped by 8.29% after the company announced a $15.1 million registered direct offering. The company plans to sell 18.4 million shares at 82 cents per share to existing investors. The proceeds will be used for research, development, working capital, and general corporate purposes. The offering is expected to close around July 10.

Portfolio Pulse from Henry Khederian

July 06, 2023 | 1:06 pm

XOM

Exxon Mobil Corp (NYSE:XOM) expects a decrease in Q2 earnings by approximately $4 billion due to lower natural gas prices and refining margins. The lower earnings may bring Exxon's net income down to around $7.5 billion. The company estimates lower Q2 earnings due to up to $2.2 billion lower earnings in the upstream division and another up to $2.2 billion decline in the energy products division. Exxon's shares are down 2.22% in the premarket session.

Portfolio Pulse from Vandana Singh

July 06, 2023 | 1:03 pm

VBIV

VBI Vaccines Inc. has announced the pricing of its underwritten public offering and concurrent registered direct offering, which are expected to generate approximately $21 million in gross proceeds. The funds will be used for the commercialization of PreHevbrio in the US, Europe, and Canada, manufacturing of PreHevbrio and clinical materials for its pipeline programs, and ongoing activities related to its development stage candidates, including VBI-1901 and VBI-2901.

Portfolio Pulse from Happy Mohamed

July 06, 2023 | 1:03 pm

PBR

SLB

Schlumberger (SLB) has been awarded a five-year contract for Petrobras' (PBR) digital transformation. The financial terms of the deal were not disclosed.

Portfolio Pulse from Benzinga Newsdesk

July 06, 2023 | 1:03 pm